drugset / Trial / NCT01069783

Study of A3309 in Patients With Dyslipidemia

NCT01069783

Phase 2 Completed 36 enrolled Albireo
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with dyslipidemia (high cholesterol levels).

Timeline

Start
2010-02
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Elobixibat Small molecule 2.5 mg
Subject Elobixibat Small molecule 5 mg

Indications